Iovance Biotherapeutics (IOVA) News Today $7.81 -0.03 (-0.38%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period 2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?December 17 at 5:29 AM | fool.comIovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn'tDecember 17 at 5:24 AM | seekingalpha.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Large Growth in Short InterestIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 56,920,000 shares, an increase of 5.4% from the November 15th total of 53,990,000 shares. Based on an average daily trading volume, of 6,130,000 shares, the days-to-cover ratio is presently 9.3 days. Currently, 23.1% of the shares of the company are sold short.December 16 at 6:06 AM | marketbeat.comState Street Corp Acquires 576,801 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)State Street Corp boosted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 4.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,201,978 shares of the biotechnology company's stock after acquiriDecember 15 at 3:52 AM | marketbeat.comPrediction: This Stock Will Beat the Market in 2025December 12, 2024 | finance.yahoo.comBNP Paribas Financial Markets Cuts Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)BNP Paribas Financial Markets decreased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 75.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 113,724 shares of the bDecember 11, 2024 | marketbeat.comAnalysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $22.33December 11, 2024 | americanbankingnews.comIovance Biotherapeutics: Steady ProgressDecember 9, 2024 | seekingalpha.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have iDecember 8, 2024 | marketbeat.com3 Monster Stocks to Hold for the Next 10 YearsDecember 7, 2024 | fool.comCharles Schwab Investment Management Inc. Has $17.96 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Charles Schwab Investment Management Inc. cut its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 3.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor ownedDecember 7, 2024 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%December 3, 2024 | finance.yahoo.comBraidwell LP Sells 1,248,682 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Braidwell LP decreased its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 85.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 217,928 shares of the biotechnology company's stock after selling 1,248,682 shares duringNovember 29, 2024 | marketbeat.com97,958 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by Intech Investment Management LLCIntech Investment Management LLC bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 97,958 shares of the biotechnology company's stock, valuedNovember 29, 2024 | marketbeat.comIovance Biotherapeutics, Inc.: Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory OfficerNovember 28, 2024 | finanznachrichten.deIs Iovance Biotherapeutics Stock a Millionaire Maker?November 27, 2024 | fool.comIovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory OfficerNovember 26, 2024 | globenewswire.comVictory Capital Management Inc. Has $1.36 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Victory Capital Management Inc. raised its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 399.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 144,280 shares of the biotechnology company's stock after acquiring an additiNovember 26, 2024 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Decreased by Eagle Asset Management Inc.Eagle Asset Management Inc. lessened its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 30.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,356,779 shares of the biotechnology company's stock afterNovember 24, 2024 | marketbeat.com65,525 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by Landscape Capital Management L.L.C.Landscape Capital Management L.L.C. purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 65,525 shares of the biotechnology coNovember 24, 2024 | marketbeat.comIovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | insidermonkey.comGot $1,500? Buy Iovance Biotherapeutics Now and Don't Look BackNovember 23, 2024 | fool.comIovance Biotherapeutics Optimizes Headquarters for Cost EfficiencyNovember 22, 2024 | markets.businessinsider.comIovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsNovember 22, 2024 | msn.com2 Innovative Stocks That Could Deliver Outsize ReturnsNovember 22, 2024 | fool.com2 Top Biotech Stocks to Buy Now and Hold For 5 Years or MoreNovember 16, 2024 | fool.comRyan D. Maynard Sells 50,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) StockNovember 15, 2024 | insidertrades.comTD Cowen Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)November 14, 2024 | markets.businessinsider.comIovance Biotherapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 13, 2024 | finance.yahoo.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Moderate Buy" by AnalystsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have giveNovember 13, 2024 | marketbeat.comPrincipal Financial Group Inc. Purchases 1,496,941 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Principal Financial Group Inc. boosted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 59.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,033,184 shares of the biotechnologyNovember 12, 2024 | marketbeat.comIovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy OpportunityNovember 11, 2024 | seekingalpha.comIovance Biotherapeutics: Strong Market Performance and Promising Clinical Results Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comIovance Biotherapeutics: Promising Growth and Expansion in Cancer Treatment Fuels Buy RatingNovember 11, 2024 | markets.businessinsider.comHC Wainwright Has Positive Estimate for IOVA FY2027 EarningsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Friday, November 8th. HC Wainwright analyst J. Pantginis now expects that the biotecNovember 11, 2024 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next YearNovember 10, 2024 | finance.yahoo.comIovance Biotherapeutics’ Strong Q3 2024 PerformanceNovember 8, 2024 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Here's WhyIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Here's WhyNovember 8, 2024 | marketbeat.comQ3 Earnings Estimate for IOVA Issued By HC WainwrightIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Iovance Biotherapeutics in a report issued on Tuesday, November 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology cNovember 8, 2024 | marketbeat.comOptimistic Outlook for Iovance Biotherapeutics with Strong Q3 Performance and Growth PotentialNovember 8, 2024 | markets.businessinsider.comIovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024November 7, 2024 | globenewswire.comA Peek at Iovance Biotherapeutics's Future EarningsNovember 7, 2024 | benzinga.comPromising Trial Results and Pipeline Expansion Justify Buy Rating for Iovance BiotherapeuticsNovember 7, 2024 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research note on Wednesday.November 6, 2024 | marketbeat.comIovance Biotherapeutics Options Trading: A Deep Dive into Market SentimentNovember 6, 2024 | benzinga.comPromising Efficacy and Long-term Response of Iovance Biotherapeutics’ Lifileucel in NSCLC: A Buy RecommendationNovember 6, 2024 | markets.businessinsider.comIovance Biotherapeutics (IOVA) Set to Announce Earnings on ThursdayIovance Biotherapeutics (NASDAQ:IOVA) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comIovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024October 31, 2024 | globenewswire.comIovance Biotherapeutics initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comUBS Initiates Coverage of Iovance Biotherapeutics (IOVA) with Buy RecommendationOctober 25, 2024 | msn.com Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. IOVA Media Mentions By Week IOVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.500.69▲Average Medical News Sentiment IOVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼77▲IOVA Articles Average Week Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Roivant Sciences News Today Ascendis Pharma A/S News Today Revolution Medicines News Today Lantheus News Today Legend Biotech News Today Nuvalent News Today Blueprint Medicines News Today Elanco Animal Health News Today Cytokinetics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
